196,900 Shares in GoodRx Holdings, Inc. $GDRX Bought by VIRGINIA RETIREMENT SYSTEMS ET Al

VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in GoodRx Holdings, Inc. (NASDAQ:GDRX) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 196,900 shares of the company’s stock, valued at approximately $981,000.

A number of other institutional investors also recently bought and sold shares of GDRX. Teacher Retirement System of Texas bought a new stake in GoodRx in the first quarter worth $218,000. Hohimer Wealth Management LLC lifted its position in GoodRx by 8.2% in the first quarter. Hohimer Wealth Management LLC now owns 35,218 shares of the company’s stock worth $155,000 after buying an additional 2,658 shares during the last quarter. SBI Securities Co. Ltd. lifted its position in shares of GoodRx by 13.8% during the first quarter. SBI Securities Co. Ltd. now owns 22,624 shares of the company’s stock worth $100,000 after purchasing an additional 2,748 shares during the last quarter. Allianz Asset Management GmbH lifted its position in shares of GoodRx by 20.3% during the first quarter. Allianz Asset Management GmbH now owns 278,077 shares of the company’s stock worth $1,226,000 after purchasing an additional 46,900 shares during the last quarter. Finally, Universal Beteiligungs und Servicegesellschaft mbH bought a new stake in shares of GoodRx during the first quarter worth $274,000. 63.77% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

Several research firms have recently weighed in on GDRX. Raymond James Financial downgraded GoodRx from a “strong-buy” rating to an “outperform” rating in a research report on Friday, August 8th. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a $6.00 price target on shares of GoodRx in a research note on Monday, August 11th. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of GoodRx in a research note on Wednesday, October 8th. Five research analysts have rated the stock with a Buy rating and seven have given a Hold rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $5.80.

Insider Transactions at GoodRx

In other GoodRx news, major shareholder Equity Vii L.P. Spectrum sold 23,771 shares of the business’s stock in a transaction that occurred on Wednesday, October 15th. The stock was sold at an average price of $4.00, for a total value of $95,084.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 4.53% of the company’s stock.

GoodRx Price Performance

GDRX opened at $3.86 on Friday. The business’s 50-day moving average is $4.24 and its two-hundred day moving average is $4.36. GoodRx Holdings, Inc. has a 1 year low of $3.31 and a 1 year high of $6.58. The company has a debt-to-equity ratio of 0.75, a current ratio of 4.21 and a quick ratio of 4.21. The firm has a market capitalization of $1.34 billion, a PE ratio of 38.60, a price-to-earnings-growth ratio of 1.64 and a beta of 1.23.

GoodRx (NASDAQ:GDRX) last issued its quarterly earnings results on Wednesday, August 6th. The company reported $0.09 earnings per share for the quarter, missing analysts’ consensus estimates of $0.10 by ($0.01). GoodRx had a return on equity of 8.86% and a net margin of 4.33%.The business had revenue of $203.07 million for the quarter, compared to analysts’ expectations of $205.72 million. During the same quarter in the previous year, the firm posted $0.08 EPS. GoodRx’s revenue was up 1.2% on a year-over-year basis. Research analysts anticipate that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current fiscal year.

GoodRx Company Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.